Literature DB >> 26136796

Pre-operative diclofenac HPβCD for pain control of needle biopsy in musculoskeletal neoplasm: preliminary results.

Antonio D'Arienzo1, Giovanni Beltrami2, Daniele Mancini2, Guido Scoccianti2, Pierluigi Cuomo2, Francesco Muratori2, Davide Matera2, Massimiliano Ippolito2, Nicola Mondanelli2, Filippo Frenos2, Francesca Totti2, Rodolfo Capanna2.   

Abstract

Needle biopsy is the main standard method used for diagnosis of musculoskeletal tumors of the limbs and superficial trunk. Pain control during this procedure is through the use of Local Anaestetic (L.A.). In order to achieve a complete pain control in our cases, recently we started using diclofenac HPβCD 50 mg via s.c. preoperativly. We present the clinical results of a non-randomized study of two eterogeneous groups of patients: "Experimental" Group (1): diclofenac HPβCD 50 mg via s.c. one hour before surgical procedure, local anesthesia and ev. diclofenac HPβCD 50 mg via s.c. 12 hours postoperative; "Conventional" Group (2): local anesthesia and ev. postoperative tramadol 100 mg via oral for pain control. In October 2014, at the Department of Orthopedic Oncology and Reconstructive Surgery of Florence, 37 musculoskeletal biopsies for a bone or a soft tissue lesion were performed. Exclusion criteria for this study were: known allergies to lidocaine, diclofenac, tramadol; known gastric or duodenal ulcers; known gastrointestinal bleed or perforation; refusal of the patients to collaborate. For one or more of these reasons, 6 patients were excluded from this study. In the Group 1, 10 patients (59%) referred no pain during the surgical procedure (8/14 biopsies on soft tissue and 2/3 on bone). In 5 cases (29%) no exacerbation of previous chronic pain, and in 2 cases (12%) a progression of local pain after biopsy (average 1 points higher in the VAS). In Group 2, only 6 patients (42%) did not have any pain during the procedure, 4 (29%) no exacerbation of previous chronic pain and 4 (29%) a progression of local pain (average 2 points higher in the VAS). Despite similar results in both Groups, Group 1 seemed to have a mild better control of perioperative pain. The use of diclofenac HPβCD 50 mg preoperative seems to be a rational approach for minimizing perioperative pain and the preliminary data of our study seem encouraging. Obviously many bias are present in this study (small numbers of cases, heterogeneity of diseases, association with local anesthetic, non-randomized study, comparison between preoperative versus postoperative treatment) and this cannot absolutely be considerate as definitive conclusions.

Entities:  

Keywords:  diclofenac HPβCD s.c.; needle biopsy musculoskeletal neoplasm; pain control

Year:  2015        PMID: 26136796      PMCID: PMC4469226          DOI: 10.11138/ccmbm/2015.12.1.047

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  13 in total

Review 1.  Pharmacogenetics of pain and analgesia.

Authors:  M T Smith; A Muralidharan
Journal:  Clin Genet       Date:  2012-08-07       Impact factor: 4.438

Review 2.  Current methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy -- a systematic review.

Authors:  Chanyang Lee; Henry H Woo
Journal:  BJU Int       Date:  2014-03       Impact factor: 5.588

3.  Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale.

Authors:  Anna Maria Carlsson
Journal:  Pain       Date:  1983-05       Impact factor: 6.961

4.  Implantable micro-chip for controlled delivery of diclofenac sodium.

Authors:  Seung Ho Lee; Min Park; Chun Gwon Park; Byung-Hwi Kim; Jieun Lee; SungYoon Choi; So-rae Nam; Sung-Hye Park; Young Bin Choy
Journal:  J Control Release       Date:  2014-09-28       Impact factor: 9.776

5.  Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man.

Authors:  D Landsdorp; T B Vree; T J Janssen; P J Guelen
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-07

Review 6.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

7.  Pharmacokinetics of a new subcutaneous diclofenac formulation administered to three body sites: quadriceps, gluteus, and abdomen.

Authors:  Salvatore Salomone; Cateno Piazza; Daniela Cristina Vitale; Francesco Cardì; Barbara Gugliotta; Filippo Drago
Journal:  Int J Clin Pharmacol Ther       Date:  2014-02       Impact factor: 1.366

8.  Efficacy and safety of low dose subcutaneous diclofenac in the management of acute pain: a randomized double-blind trial.

Authors:  Thomas Dietrich; Rachel Leeson; Barbara Gugliotta; Birte Petersen
Journal:  Pain Pract       Date:  2013-05-22       Impact factor: 3.183

Review 9.  Cancer-related inflammation and treatment effectiveness.

Authors:  Connie I Diakos; Kellie A Charles; Donald C McMillan; Stephen J Clarke
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

10.  Subcutaneous injection of diclofenac for the treatment of pain following minor orthopedic surgery (DIRECT study): a randomized trial.

Authors:  Eugenio Chiarello; Stefano Bernasconi; Barbara Gugliotta; Sandro Giannini
Journal:  Pain Pract       Date:  2013-11-27       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.